Diabetic cardiomyopathy: where we are and where we are going

키워드

참고문헌 (139)

1. Pappachan JM, "Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management", World J Diabetes, 4, pp.177~189 (2013)
2. Wang ZV, "Diabetic cardiomyopathy: catabolism driving metabolism", Circulation, 131, pp.771~773 (2015)
3. Trachanas K, "Diabetic cardiomyopathy:from pathophysiology to treatment", Hellenic J Cardiol, 55, pp.411~421 (2014)
4. Finck BN, "The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus", J Clin Invest, 109, pp.121~130 (2002)
5. Aneja A, "Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options", Am J Med, 121, pp.748~757 (2008)
6. Kannel WB, "Diabetes and cardiovascular disease:the Framingham study", JAMA, 241, pp.2035~2038 (1979)
7. Ryden L, "Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: results from the ATLAS trial", Eur Heart J, 21, pp.1967~1978 (2000)
8. Shindler DM, "Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry", Am J Cardiol, 77, pp.1017~1020 (1996)
9. Jia G, "Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy", Nat Rev Endocrinol, 12, pp.144~153 (2016)
10. Wong AK, "Insulin resistance:a potential new target for therapy in patients with heart failure", Cardiovasc Ther, 26, pp.203~213 (2008)
11. Aroor AR, "Insulin resistance and heart failure: molecular mechanisms", Heart Fail Clin, 8, pp.609~617 (2012)
12. Maisch B, "Diabetic cardiomyopathy:fact or fiction?", Herz, 36, pp.102~115 (2011)
13. Witteles RM, "Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options", J Am Coll Cardiol, 51, pp.93~102 (2008)
14. Nicolino A, "Left ventricular diastolic filling in diabetes mellitus with and without hypertension", Am J Hypertens, 8, pp.382~389 (1995)
15. Redfield MM, "Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic", JAMA, 289, pp.194~202 (2003)
16. Konduracka E, "Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study", Acta Diabetol, 50, pp.597~606 (2013)
17. Fang ZY, "Diabetic cardiomyopathy:evidence, mechanisms, and therapeutic implications", Endocr Rev, 25, pp.543~567 (2004)
18. Nishikawa T, "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage", Nature, 404, pp.787~790 (2000)
19. Cai L, "Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway", Diabetes, 51, pp.1938~1948 (2002)
20. Aragno M, "Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes", Endocrinology, 147, pp.5967~5974 (2006)
21. Du X, "Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells", J Clin Invest, 112, pp.1049~1057 (2003)
22. Gawlowski T, "Heat shock protein 27 modification is increased in the human diabetic failing heart", Horm Metab Res, 41, pp.594~599 (2009)
23. Petrova R, "Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes", J Mol Cell Cardiol, 34, pp.1425~1431 (2002)
24. Feng B, "Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level", Am J Physiol Endocrinol Metab, 294, pp.E1119~E1126 (2008)
25. Factor SM, "Coronary microvascular abnormalities in the hypertensive-diabetic rat: a primary cause of cardiomyopathy?", Am J Pathol, 116, pp.9~20 (1984)
26. Adameova A, "Role of microangiopathy in diabetic cardiomyopathy", Heart Fail Rev, 19, pp.25~33 (2014)
27. Zhou X, "Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat", Hypertension, 55, pp.880~888 (2010)
28. Hayden MR, "Ultrastructure study of transgenic Ren2 rat aorta. Part 1: rndothelium and intima", Cardiorenal Med, 2, pp.66~82 (2012)
29. Campbell DJ, "Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease", Cardiovasc Diabetol, 10, pp.80~ (2011)
30. Blaha MJ, "The relationship between insulin resistance and incidence and progression of coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis (MESA)", Diabetes Care, 34, pp.749~751 (2011)
31. Olesen P, "Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin", Am J Physiol Heart Circ Physiol, 292, pp.H1058~H1064 (2007)
32. Yuan LQ, "RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells", PLoS One, 6, pp.e29037~ (2011)
33. Mandavia CH, "Over-nutrition and metabolic cardiomyopathy", Metabolism, 61, pp.1205~1210 (2012)
34. Dhalla NS, "Subcellular remodeling and heart dysfunction in chronic diabetes", Cardiovasc Res, 40, pp.239~247 (1998)
35. Liu J, "Targeting mitochondrial biogenesis for preventing and treating insulin resistance in diabetes and obesity: hope from natural mitochondrial nutrients", Adv Drug Deliv Rev, 61, pp.1343~1352 (2009)
36. Falcao-Pires I, "Diabetic cardiomyopathy:understanding the molecular and cellular basis to progress in diagnosis and treatment", Heart Fail Rev, 17, pp.325~344 (2012)
37. Adeghate E, "Structural changes in the myocardium during diabetes-induced cardiomyopathy", Heart Fail Rev, 19, pp.15~23 (2014)
38. Schaffer SW., "Cardiomyopathy associated with noninsulin-dependent diabetes", Mol Cell Biochem, 107, pp.1~20 (1991)
39. Battiprolu PK, "Diabetic cardiomyopathy and metabolic remodeling of the heart", Life Sci, 92, pp.609~615 (2013)
40. Harmancey R, "Insulin resistance improves metabolic and contractile efficiency in stressed rat heart", FASEB J, 26, pp.3118~3126 (2012)
41. McGavock JM, "Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study", Circulation, 116, pp.1170~1175 (2007)
42. Rijzewijk LJ, "Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus", J Am Coll Cardiol, 52, pp.1793~1799 (2008)
43. Rijzewijk LJ, "Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy:studies with cardiac positron emission tomography and magnetic resonance imaging", J Am Coll Cardiol, 54, pp.1524~1532 (2009)
44. van de Weijer T, "Lipotoxicity in type 2 diabetic cardiomyopathy", Cardiovasc Res, 92, pp.10~18 (2011)
45. Balaban RS., "Cardiac energy metabolism homeostasis:role of cytosolic calcium", J Mol Cell Cardiol, 34, pp.1259~1271 (2002)
46. Iyngkaran P, "The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes", Diabetes Metab, 39, pp.290~298 (2013)
47. Olshansky B, "Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy", Circulation, 118, pp.863~871 (2008)
48. Pappachan JM, "Cardiac autonomic neuropathy in diabetes mellitus: prevalence, risk factors and utility of corrected QT interval in the ECG for its diagnosis", Postgrad Med J, 84, pp.205~210 (2008)
49. Di Carli MF, "Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus", Circulation, 100, pp.813~819 (1999)
50. Taskiran M, "Decreased myocardial perfusion reserve in diabetic autonomic neuropathy", Diabetes, 51, pp.3306~3310 (2002)
51. Erbas T, "Plasma big-endothelin levels, cardiac autonomic neuropathy, and cardiac functions in patients with insulin-dependent diabetes mellitus", Clin Cardiol, 23, pp.259~263 (2000)
52. iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM:comparison with cardiovascular reflex tests and relationship to left ventricular function, "Diabetes", 1995, 543~549
53. Kumar R, "Intracardiac intracellular angiotensin system in diabetes", Am J Physiol Regul Integr Comp Physiol, 302, pp.R510~R517 (2012)
54. Kurdi M, "New take on the role of angiotensin II in cardiac hypertrophy and fibrosis", Hypertension, 57, pp.1034~1038 (2011)
55. Frustaci A, "Myocardial cell death in human diabetes", Circ Res, 87, pp.1123~1132 (2000)
56. DeMarco VG, "The pathophysiology of hypertension in patients with obesity", Nat Rev Endocrinol, 10, pp.364~376 (2014)
57. McMaster WG, "Inflammation, immunity, and hypertensive end-organ damage", Circ Res, 116, pp.1022~1033 (2015)
58. Hofmann U, "Role of lymphocytes in myocardial injury, healing, and remodeling after myocardial infarction", Circ Res, 116, pp.354~367 (2015)
59. Jia G, "Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet", Hypertension, 65, pp.531~539 (2015)
60. Mori J, "ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4", Am J Physiol Heart Circ Physiol, 304, pp.H1103~H1113 (2013)
61. Asrih M, "Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome", Mediators Inflamm, 2013, pp.367245~ (2013)
62. Weirather J, "Foxp3+CD4+ T cells improve healing after myocardial infarction by modulating monocyte", macrophage differentiation, 2014, pp.115, 55~67
63. Sell H, "Adaptive immunity in obesity and insulin resistance", Nat Rev Endocrinol, 8, pp.709~716 (2012)
64. Ait-Oufella H, "Natural regulatory T cells control the development of atherosclerosis in mice", Nat Med, 12, pp.178~180 (2006)
65. Yu Q, "T-lymphocytes mediate left ventricular fibrillar collagen cross-linking and diastolic dysfunction in mice", Matrix Biol, 29, pp.511~518 (2010)
66. Cao Y, "Adoptive transfer of regulatory T cells protects against coxsackievirus B3-induced cardiac fibrosis", PLoS One, 8, pp.e74955~ (2013)
67. Voulgari C, "Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies", Vasc Health Risk Manag, 6, pp.883~903 (2010)
68. Nunes S, "Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker", Cardiovasc Diabetol, 12, pp.44~ (2013)
69. Landsberg L, "Diabetes and hypertension:pathogenesis, prevention and treatment", Clin Exp Hypertens, 26, pp.621~628 (2004)
70. Mathis DR, "Effect of hypertension on the development of diabetic cardiomyopathy", Can J Physiol Pharmacol, 78, pp.791~798 (2000)
71. Aijaz B, "Abnormal cardiac structure and function in the metabolic syndrome: a population-based study", Mayo Clin Proc, 83, pp.1350~1357 (2008)
72. Chavali V, "Predictors and prevention of diabetic cardiomyopathy", Diabetes Metab Syndr Obes, 6, pp.151~160 (2013)
73. Ernande L, "Diabetic cardiomyopathy:myth or reality?", Arch Cardiovasc Dis, 105, pp.218~225 (2012)
74. Battiprolu PK, "Diabetic cardiomyopathy: mechanisms and therapeutic targets", Drug Discov Today Dis Mech, 7, pp.e135~e143 (2010)
75. Khouri SJ, "A practical approach to the echocardiographic evaluation of diastolic function", J Am Soc Echocardiogr, 17, pp.290~297 (2004)
76. Yu CM, "Tissue Doppler imaging a new prognosticator for cardiovascular diseases", J Am Coll Cardiol, 49, pp.1903~1914 (2007)
77. Miki T, "Diabetic cardiomyopathy:pathophysiology and clinical features", Heart Fail Rev, 18, pp.149~166 (2013)
78. Gottlieb I, "Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: current applications and future perspectives", Heart Fail Rev, 11, pp.313~323 (2006)
79. Paulus WJ, "How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology", Eur Heart J, 28, pp.2539~2550 (2007)
80. Dinh W, "Increased levels of laminin and collagen type VI may reflect early remodelling in patients with acute myocardial infarction", Acta Cardiol, 64, pp.329~334 (2009)
81. D’Souza A, "Left ventricle structural remodelling in the prediabetic Goto-Kakizaki rat", Exp Physiol, 96, pp.875~888 (2011)
82. Quilliot D, "Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance", Int J Obes (Lond), 29, pp.1321~1328 (2005)
83. Stolen TO, "Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy", Circ Res, 105, pp.527~536 (2009)
84. Epp RA, "Exercise training prevents the development of cardiac dysfunction in the low-dose streptozotocin diabetic rats fed a high-fat diet", Can J Physiol Pharmacol, 91, pp.80~89 (2013)
85. Epshteyn V, "Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes", Diabetes Care, 26, pp.2081~2087 (2003)
86. Russell NE, "Troponin T and pro-B-type natriuretic peptide in fetuses of type 1 diabetic mothers", Diabetes Care, 32, pp.2050~2055 (2009)
87. Feng B, "miR133a regulates cardiomyocyte hypertrophy in diabetes", Diabetes Metab Res Rev, 26, pp.40~49 (2010)
88. Rijzewijk LJ, "Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes", J Am Coll Cardiol, 56, pp.225~233 (2010)
89. Kodama S, "Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis", Diabetes Care, 36, pp.471~479 (2013)
90. Sharma AK, "Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2diabetes mellitus rats", Eur J Pharm Sci, 38, pp.433~444 (2009)
91. Aboukhoudir F, "Left ventricular systolic function deterioration during dobutamine stress echocardiography as an early manifestation of diabetic cardiomyopathy and reversal by optimized therapeutic approach", Int J Cardiovasc Imaging, 28, pp.1329~1339 (2012)
92. Chung J, "Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemic control", J Am Coll Cardiol, 47, pp.384~390 (2006)
93. Zib I, "Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes", J Investig Med, 55, pp.230~236 (2007)
94. Xie Z, "Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice", Diabetes, 60, pp.1770~1778 (2011)
95. von Bibra H, "Impact of diabetes on postinfarction heart failure and left ventricular remodeling", Curr Heart Fail Rep, 8, pp.242~251 (2011)
96. Wong AK, "The effect of metformin on insulin resistance and exercise parameters in patients with heart failure", Eur J Heart Fail, 14, pp.1303~1310 (2012)
97. Mamas MA, "Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?", J Card Fail, 16, pp.761~768 (2010)
98. Sacca L, "Insulin resistance in chronic heart failure: a difficult bull to take by the horns", Nutr Metab Cardiovasc Dis, 19, pp.303~305 (2009)
99. Caglayan E, "Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis", Diabetes, 57, pp.2470~2479 (2008)
100. Younce CW, "Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a", Am J Physiol Cell Physiol, 304, pp.C508~C518 (2013)
101. Doehner W, "Metabolic impairment in heart failure: the myocardial and systemic perspective", J Am Coll Cardiol, 64, pp.1388~1400 (2014)
102. Witteles RM, "Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy", J Card Fail, 18, pp.804~809 (2012)
103. Bostick B, "Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity", Metabolism, 63, pp.1000~1011 (2014)
104. Adeghate E, "Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function", Open Med Chem J, 5, pp.78~81 (2011)
105. Inzucchi SE, "SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials", Diab Vasc Dis Res, 12, pp.90~100 (2015)
106. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
107. Thomas CM, "Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor", Clin Sci (Lond), 124, pp.529~541 (2013)
108. Machackova J, "Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes", Mol Cell Biochem, 261, pp.271~278 (2004)
109. Symeonides P, "Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study", Eur J Echocardiogr, 8, pp.480~486 (2007)
110. Sharma V, "Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: confronting the maze", World J Cardiol, 3, pp.281~302 (2011)
111. Mohamad HE, "Management of cardiac fibrosis in diabetic rats: the role of peroxisome proliferator activated receptor gamma (PPAR-gamma)and calcium channel blockers (CCBs)", Diabetol Metab Syndr, 3, pp.4~ (2011)
112. Giannetta E, "Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging", Circulation, 125, pp.2323~2333 (2012)
113. Chen YH, "Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis", Exp Clin Endocrinol Diabetes, 120, pp.116~120 (2012)
114. Cholesterol Treatment Trialists’ (CTT) Collaborators, "Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis", Lancet, 371, pp.117~125 (2008)
115. Van Linthout S, "Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy", Diabetologia, 50, pp.1977~1986 (2007)
116. Dai QM, "Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor", Chin Med J (Engl), 124, pp.89~94 (2011)
117. Nickel A, "Myocardial energetics in heart failure", Basic Res Cardiol, 108, pp.358~ (2013)
118. Gao D, "Trimetazidine: a meta-analysis of randomised controlled trials in heart failure", Heart, 97, pp.278~286 (2011)
119. Zhao P, "The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy", Life Sci, 92, pp.633~638 (2013)
120. Li YJ, "Improvement of mechanical heart function by trimetazidine in db", db mice, 2010, pp.31, 560~569
121. Maier LS, "RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study", JACC Heart Fail, 1, pp.115~122 (2013)
122. Senanayake EL, "Multicentre double-blind randomized controlled trial of perhexiline as a metabolic modulator to augment myocardial protection in patients with left ventricular hypertrophy undergoing cardiac surgery", Eur J Cardiothorac Surg, 48, pp.354~362 (2015)
123. Li CJ, "Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid", Cardiovasc Diabetol, 11, pp.73~ (2012)
124. Delucchi F, "Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats", PLoS One, 7, pp.e39836~ (2012)
125. Wang G, "Luteolin ameliorates cardiac failure in type I diabetic cardiomyopathy", J Diabetes Complications, 26, pp.259~265 (2012)
126. Wang G, "Riboflavin alleviates cardiac failure in type I diabetic cardiomyopathy", Heart Int, 6, pp.e21~ (2011)
127. Xu X, "Cardioprotective effect of sodium ferulate in diabetic rats", Int J Med Sci, 9, pp.291~300 (2012)
128. Sulaiman M, "Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy", Am J Physiol Heart Circ Physiol, 298, pp.H833~H843 (2010)
129. Rabassa M, "Resveratrol metabolite profiling in clinical nutrition research: from diet to uncovering disease risk biomarkers: epidemiological evidence", Ann N Y Acad Sci, 1348, pp.107~115 (2015)
130. Xu YJ, "Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants", Heart Fail Rev, 19, pp.113~121 (2014)
131. Szeto HH., "First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics", Br J Pharmacol, 171, pp.2029~2050 (2014)
132. Huynh K, "Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db", db mouse model of type 2diabetes, 2012, pp.55, 1544~1553
133. Mortensen SA, "The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial", JACC Heart Fail, 2, pp.641~649 (2014)
134. Huynh K, "Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways", Pharmacol Ther, 142, pp.375~415 (2014)
135. Meloni M, "Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice", Diabetes, 61, pp.229~240 (2012)
136. Katare R, "Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling", Circ Res, 108, pp.1238~1251 (2011)
137. Greco S, "MicroRNA dysregulation in diabetic ischemic heart failure patients", Diabetes, 61, pp.1633~1641 (2012)
138. Chen H, "Micro-RNA-195and -451 regulate the LKB1", AMPK signaling axis by targeting MO25, 2012, pp.7, e41574~
139. Cheng Y, "Transplantation of bone marrow-derived endothelial progenitor cells attenuates myocardial interstitial fibrosis and cardiac dysfunction in streptozotocin-induced diabetic rats", Int J Mol Med, 30, pp.870~876 (2012)